NEW YORK, Dec 10 (Reuters) - Online telehealth company Hims and Hers Health is launching its weight-loss membership and ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question. Check out the current price ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

・Retail traders ranked Novo Nordisk as the strongest long-term obesity play in a 1,100-vote poll. ・Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector. ...

The telehealth company Hims & Hers Health is accelerating its international growth strategy, with a new launch in the United Kingdom marking its latest move. This follows closely on the heels of its ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Hims & Hers Health reported strong 3Q25 revenue growth of 49% YoY, despite a GAAP EPS miss and shares falling post-earnings. HIMS is expanding its offerings, including testosterone and potential ...